Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Artelo Biosciences announced a U.S. Patent and Trademark Office Notice of Allowance for the intended commercial formulation of its lead asset ART27.13, potentially extending patent protection through 2041. ART27.13 is a peripherally selective cannabinoid agonist currently in two Phase 2 studies: the CAReS trial for cancer-related anorexia and the DREAM study for glaucoma or ocular hypertension.
Key figures
- Drug Name
- ART27.13
- Phase Of Trial
- Phase 2
- Dose low mcg
- 650
- Dose high mcg
- 1300
- Patent expiry year
- 2041
- Participants studies
- 280
- Weight loss placebo pct
- ~5%
- Weight gain high dose pct
- +6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.